Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
The AD8 (Ascertain Dementia 8) is a brief screening tool that helps identify whether someone may have mild cognitive impairment (MCI) by asking eight specific questions about changes in memory and thinking. Developed by the Knight Alzheimer Disease Research Center at Washington University, the AD8 has become one of the most widely used screening instruments in primary care, geriatric clinics, and memory centers because it can be administered quickly—often in just five to ten minutes—and requires no special equipment or training. When someone scores 2 or higher on the AD8, it suggests cognitive changes that warrant further medical evaluation, though the test is designed to screen for potential problems rather than provide a definitive diagnosis.
The AD8 addresses a critical gap in early detection: many people with mild cognitive impairment go undiagnosed because they don’t receive regular cognitive screening, yet catching cognitive decline early can allow for timely interventions, lifestyle modifications, and medical management that may slow progression. For example, a 75-year-old woman whose adult daughter notices she’s started repeating the same questions multiple times during phone calls might score elevated on the AD8, prompting her doctor to order additional cognitive testing and potentially uncovering early Alzheimer’s disease when treatment options are most effective. The test’s value lies not in diagnosing disease but in raising a red flag that something deserves a closer look.
Table of Contents
- How Does the AD8 Test Work and What Constitutes a Positive Screening?
- Diagnostic Accuracy and Reliability of the AD8 for Mild Cognitive Impairment
- Informant-Based Versus Self-Administered AD8: Which Version Should Be Used?
- Using the AD8 Test in Primary Care and Clinical Practice Settings
- Limitations and Potential Pitfalls of the AD8 Screening Approach
- Emerging Evidence on Optimized AD8 Cutoff Values and Clinical Implications
- The AD8 Within the Broader Landscape of Cognitive Screening and Future Directions
- Conclusion
How Does the AD8 Test Work and What Constitutes a Positive Screening?
The ad8 consists of eight questions that informants (usually family members or close caregivers) answer based on whether they’ve noticed changes in the person’s cognition over the past several years. The questions assess changes in memory, ability to handle finances or medications, repeating oneself, difficulty making decisions, getting lost, confusion about time or place, trouble with hobbies or social activities, and requiring reminders for important information. Each answer receives a score, and the standard interpretation is straightforward: a total score of 0 to 1 indicates normal cognition, while a score of 2 or higher raises concern for possible cognitive impairment and suggests the need for further evaluation.
The appeal of the AD8 lies in its simplicity and speed, which makes it practical for busy clinical settings. A neurologist can administer it in a few minutes during a routine office visit, whereas comprehensive neuropsychological testing might require several hours and hundreds of dollars in fees. However, the test’s brevity also means it captures only a snapshot of cognitive function and cannot replace detailed assessment. The distinction between who answers the questions—the person being screened or an informant—turns out to matter significantly for accuracy, a point that clinicians and families often overlook when interpreting results.
Diagnostic Accuracy and Reliability of the AD8 for Mild Cognitive Impairment
Recent systematic reviews and meta-analyses examining the AD8’s performance for detecting mild cognitive impairment found considerable variation in how well the test performs depending on who completes it. When an informant (someone who knows the person well, like a spouse, adult child, or close friend) answers the AD8 questions, the test achieves approximately 80% sensitivity and 79% specificity for identifying mild cognitive impairment—meaning it correctly identifies about 80% of people who actually have MCI while avoiding false alarms in about 79% of those with normal cognition. In contrast, when people complete the AD8 about themselves (known as the self-administered or participant-rated version), sensitivity drops significantly to 57% while specificity remains around 71%, indicating that people are often unaware of their own cognitive changes or underestimate their severity.
This difference underscores an important limitation: people with emerging cognitive impairment frequently lack insight into their own decline, a phenomenon called anosognosia that’s particularly common in Alzheimer’s disease and related conditions. Someone with mild memory problems might genuinely believe their thinking is intact, while their spouse has noticed they can no longer manage the household bills or navigate to familiar places. For this reason, the informant-based AD8 is far more valuable in clinical practice, though it requires finding a suitable informant who has regular contact with the person—a challenge for isolated older adults without family nearby. The test’s internal consistency is strong, with a Cronbach’s alpha of 0.84, meaning the eight items reliably measure the same underlying concept of cognitive change.
Informant-Based Versus Self-Administered AD8: Which Version Should Be Used?
The difference between informant-based and self-administered AD8 testing represents one of the most clinically significant findings in the screening literature, yet many primary care physicians are not fully aware of this distinction. The informant-based version (iAD8)—which provides superior sensitivity and specificity—should be the preferred approach whenever possible, particularly in initial screening. In practice, this might mean scheduling a brief telehealth call with a family member or asking someone to come along to the appointment to answer the screening questions, a small effort that substantially improves diagnostic accuracy.
Some clinics use a hybrid approach: they administer both the informant-based and self-rated versions, and when they disagree significantly—for instance, if an informant reports marked decline but the patient denies any problems—this discordance itself becomes clinically meaningful and warrants further investigation. The self-administered version still has limited utility in certain contexts, such as when no reliable informant is available, when monitoring self-awareness as part of cognitive assessment, or when someone insists on completing the screening alone. However, relying solely on a patient’s self-report AD8 score risks missing early cognitive impairment, particularly in conditions like early-onset Alzheimer’s disease where people may actively deny or downplay symptoms. Clinicians must weigh convenience against accuracy and, when possible, prioritize obtaining collateral information from someone who interacts regularly with the patient.
Using the AD8 Test in Primary Care and Clinical Practice Settings
The AD8 functions as a gatekeeper test in clinical practice, identifying who needs more comprehensive evaluation rather than serving as a diagnostic tool itself. When someone screens positive (score ≥2), the recommended next step is more detailed cognitive assessment using instruments like the Mini-Mental State Examination (MMSE), the Montreal Cognitive Assessment (MoCA), or referral to a neuropsychologist for comprehensive testing. This tiered approach is practical and cost-effective: the AD8 quickly identifies people at risk, while further testing focuses resources on those who actually need it.
Research shows that the AD8 performs better in clinical and hospital settings than in community-based screening programs, a finding with real implications for how it should be used. When a primary care doctor uses the AD8 during an office visit—either because the patient or family expressed concerns or because cognitive screening is part of the clinician’s routine for older adults—the test’s accuracy improves. In contrast, large-scale community screening programs using the AD8 have generated more false positives, potentially creating unnecessary worry. The test’s intended role is therefore as a clinical tool within the healthcare system rather than as a mass-screening instrument for asymptomatic populations, though some experts advocate for opportunistic screening in high-risk groups during medical encounters.
Limitations and Potential Pitfalls of the AD8 Screening Approach
Despite its utility, the AD8 has important limitations that clinicians and families should understand. The standard cutoff score of ≥2 was established based on earlier research, but more recent 2025 studies examining optimized cutoff values suggest this threshold may produce an unacceptably high false positive rate in certain populations. Researchers found that using a cutoff of 3 to 4 better identifies mild cognitive impairment while reducing false alarms, and using a cutoff of ≥5 for dementia detection yields superior specificity. This means some people who score 2 on the traditional scale may not actually have cognitive impairment—they might have minor forgetfulness, depression causing memory complaints, or medication side effects mimicking cognitive decline.
Another limitation involves the cultural and educational context in which the AD8 is administered. The eight questions assume certain knowledge and experiences—such as managing finances or using technology for communication—that may not apply universally across all socioeconomic, educational, and cultural backgrounds. Additionally, the AD8 cannot differentiate between the cause of cognitive impairment; a positive screen might indicate Alzheimer’s disease, vascular dementia, Parkinson’s disease dementia, frontotemporal dementia, or other conditions, and it may also catch depression-related cognitive complaints rather than true neurodegeneration. For these reasons, a positive AD8 should never be interpreted as a diagnosis—it’s a signal to pursue further evaluation, not an endpoint.
Emerging Evidence on Optimized AD8 Cutoff Values and Clinical Implications
Recent research from 2025 has challenged the traditional AD8 scoring and suggests that optimized cutoff values substantially improve the test’s clinical utility. Studies examining large datasets found that using a cutoff of ≥5 for detecting dementia achieved sensitivity of 100% and specificity of 96.3%, while using a cutoff of 3 to 4 for detecting mild cognitive impairment produced 81.67% sensitivity and 93.59% specificity. These are meaningful improvements over the standard ≥2 cutoff, particularly in reducing false positives that create unnecessary alarm and lead to redundant testing.
However, these newer cutoff recommendations haven’t yet been universally adopted in clinical practice, creating a transition period where different clinics may use different standards. Some healthcare systems and practices continue using the traditional ≥2 threshold, while others, particularly academic medical centers and dementia specialists, are beginning to implement the optimized cutoffs. For patients and families, this means that a person who scores 2 or 3 on an AD8 administered by their primary care doctor might be reassured as normal, while the same person evaluated at a memory clinic using updated scoring protocols might be referred for further assessment. Over time, standardization around the more accurate cutoff values will likely improve the test’s clinical reliability, but during this transition, awareness of which cutoff a clinician is using is important context for understanding test results.
The AD8 Within the Broader Landscape of Cognitive Screening and Future Directions
The AD8 remains an essential part of cognitive screening in clinical practice, but it operates within a growing ecosystem of cognitive assessment tools, biomarker testing, and digital health innovations that are changing how dementia risk is identified and monitored. While the AD8 is quick and inexpensive, newer approaches like blood-based biomarkers for amyloid, tau, and phosphorylated tau protein can detect Alzheimer’s pathology years before symptoms appear, potentially identifying people who would benefit from newer disease-modifying drugs.
The role of screening instruments like the AD8 is evolving from being the primary gate-keeper for further assessment toward being one component of a more integrated approach to brain health screening. Future developments may include refinement of the AD8 for use in digital or remote settings, integration with electronic health records to flag cognitive decline based on repeated testing over time, and combination of AD8 screening with biomarker results to provide more personalized risk stratification. For now, the AD8 remains most valuable as the practical, accessible first step in identifying cognitive concerns in a diverse range of clinical settings, particularly when an informant-based version can be obtained and when results are interpreted using the emerging evidence on optimized cutoff values.
Conclusion
The AD8 test serves as a valuable and practical screening tool for identifying potential mild cognitive impairment, with strong evidence supporting its use when an informant provides the responses. With informant-based administration, the test achieves approximately 80% sensitivity and 79% specificity for detecting mild cognitive impairment, making it one of the most useful quick-screening instruments available in primary care, geriatric medicine, and neurology. However, key limitations include the dramatic drop in accuracy when people self-administer the test, the need for interpretation using updated cutoff values rather than the traditional threshold, and the test’s inability to diagnose the cause of cognitive impairment or serve as a definitive diagnostic tool.
If you or a family member has concerns about cognitive changes, discussing AD8 screening with your doctor is a practical first step, particularly if an informant can participate in the assessment. A positive screen should prompt further evaluation with more comprehensive cognitive testing or neuropsychological assessment, but it need not cause panic—many people who screen positive on the AD8 have reversible causes of cognitive complaints or milder changes than initially suspected. Understanding both the strengths and limitations of the AD8 helps ensure it’s used appropriately as a helpful screening tool rather than misinterpreted as a diagnosis, keeping its role appropriately positioned within the broader context of brain health assessment and dementia prevention.
